Although she was feeling improved, restaging scans obtained 5 months into BRAF/MEK therapy showed a progression in peritoneal, splenic, pelvic, and uterine implants but a decrease in metastatic disease in the liver and psoas. The gene discussed is MAP2K7; the disease is metastatic neoplasm.